LLY vs YCBD

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

cbdMD, Inc. (YCBD) remains an extremely high-risk, speculative investment with very limited 10x growth potential within 3-5 years. The $10M market cap continues to signal severe financial distress, precarious operations, and ongoing struggles with competitive differentiation and profitability. No material positive changes have occurred in the 24 days since the last review. The company faces persis...